PASCAL
4Pages

Empowering. Effective. Safe. Introducing the Edwards PASCAL Transcatheter Valve Repair System Empowering and effective MR reduction that respects the native anatomy Empowering Transform the way you see mitral valve repair Driven by a passion to help patients. With over 60 years of experience in creating new therapies and procedures that elevate care in meaningful ways, Edwards Lifesciences is the global leader in patient-focused medical innovations. For more information, please visit www.Edwards.com/PASCAL or contact us at pascal_info@edwards.com References 1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-1011. 2. Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014;63:185-186. 3. Praz F, Spargias K, Chrissoheris M et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet. 2017;390(10096):773-780. For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events. Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity. Edwards, Edwards Lifesciences, the stylized E logo, and PASCAL are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners. © 2019 Edwards Lifesciences Corporation. All rights reserved. E8830/01-19/TMTT Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com Introducing the CE Mark approved Edwards PASCAL Transcatheter Valve Repair S

Mitral regurgitation: complex disease with limited options Mitral regurgitation (MR) occurs in approximately 2% of the population, with up to 10% of people over 75 years old affected1 Medically managed patients with severe MR have poor outcomes 2: Mortality rate Proportion of surviving patients hospitalised for heart failure2 Introducing the PASCAL Repair System An empowering transcatheter mitral valve repair system that effectively reduces MR while respecting the native anatomy • Enables optimised leaflet capture • Designed for effective MR reduction 3 • Helps promote procedural saf

Optimised leaflet capture Designed for effective mitral regurgitation reduction 3 Empowering Edwards delivery system with direct manoeuvring in three planes to improve procedural efficiency Helps deliver the desired outcomes while respecting the native anatomy Contoured paddles designed to reduce stress on leaflets Broad paddles create a wide capture area for simplified leaflet capture Independent leaflet capture supports gentle interaction and enables operators to capture leaflets in difficult pathologies Broad paddles designed to maximise leaflet coaptation Central spacer fills the...

Excellent safety profile Contoured paddles and a unique central spacer are designed to reduce leaflet stress while implant elongation helps promote safe subvalvular manoeuvring Contoured paddles Unique central spacer Implant elongation